Joseph Mikhael

Joseph Mikhael, M.D., is a Professor in the Clinical Genomics and Therapeutics Division at the Translational Genomics Research Institute (TGen), part of City of Hope. He concurrently serves as Chief Medical Officer of the International Myeloma Foundation (IMF) and Director of Myeloma Research at the HonorHealth Research Institute, where he leads phase 1 clinical trials. Previously, he held key roles at Mayo Clinic Arizona, including Professor, Associate Dean of Graduate Medical Education, and Deputy Director for Education at the Mayo Clinic Cancer Center.

Education

Dr. Mikhael completed his medical training in Ottawa, Canada, followed by a Hematology Residency at Princess Margaret Hospital (Toronto). He subsequently pursued a Multiple Myeloma Fellowship and a Master's Degree in Education from the University of Toronto.

Research Focus

His clinical expertise centers on plasma cell disorders—multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He leads numerous clinical trials and explores pharmaco-economics, medical communication, and global health equity. His work emphasizes innovative therapies and reducing disparities in myeloma care, notably through the IMF's M-Power initiative targeting African American communities.

Publications & Impact

With over 150 peer-reviewed articles, Dr. Mikhael's research spans clinical trial design, treatment guidelines, adverse event management, and medical education. His publications frequently address therapeutic sequencing, drug efficacy, and adaptive strategies for refractory myeloma, reflecting a consistent focus on improving patient survival and care standards.

Awards

• Mayo Clinic Resident and Fellow Association Hall of Fame (Educator of the Year)
• Top 100 Doctors in the United States

Leadership & Global Engagement

He chairs the IMF's M-Power project to address racial disparities in myeloma outcomes and dedicates 20% of his time to improving treatment access in underserved regions. An active member of the International Myeloma Working Group, he also contributes to the Journal of Clinical Oncology's editorial board and has shaped ASCO/ASH clinical guidelines.